{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:10:29Z","timestamp":1792001429830,"version":"4.4.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>The discovery of antibody-drug conjugates (ADCs) has revolutionized the therapeutic landscape of oncology patients, especially those suffering from breast cancer. Following the approval of the first ADC for solid tumors in breast cancer, numerous additional ADCs have also been launched in the therapeutic landscape of breast cancer and have become the new standard of care for all diverse subtypes. Sacituzumab tirumotecan (sac-TMT) (MK-2870\/SKB264) is an innovative ADC targeting TROP2 and delivering a belotecan-derived topoisomerase I inhibitor payload. Several clinical trials of sac-TMT have demonstrated promising results including improved overall response and disease control rates as well as progression-free survival. The safety profile of sac-TMT seems easily manageable; adverse events include mainly grade 1\/2 nausea and alopecia, while grade 3\/4 neutropenia and leukopenia and grade 3\/4 stomatitis have been also reported. However, no treatment-related deaths have been reported so far. Since sac-TMT offers an encouraging new option for diverse breast cancer populations with manageable toxicity profiles, this review aims to summarize the recent published data regarding its use in breast cancer.<\/jats:p>","DOI":"10.3389\/or.2026.1781533","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:46:05Z","timestamp":1770273965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Sacituzumab tirumotecan (sac-TMT\/MK-2870\/SKB264): a novel antibody\u2013drug conjugate in breast cancer"],"prefix":"10.3389","volume":"20","author":[{"given":"Amalia A.","family":"Sofianidi","sequence":"first","affiliation":[{"name":"Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens School of Medicine","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkistis","family":"Papatheodoridi","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, Alexandra General Hospital of Athens, School of Medicine, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Dimitrakakis","sequence":"additional","affiliation":[{"name":"First Department of Obstetrics and Gynecology, General Hospital of Athens Alexandra, School of Medicine, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Marinopoulos","sequence":"additional","affiliation":[{"name":"First Department of Obstetrics and Gynecology, General Hospital of Athens Alexandra, School of Medicine, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Michalaki","sequence":"additional","affiliation":[{"name":"Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens School of Medicine","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[{"name":"Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens School of Medicine","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/pharmaceutics15082160","article-title":"Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload","volume":"15","author":"Kondrashov","year":"2023","journal-title":"Pharmaceutics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e390094","DOI":"10.1200\/EDBK_390094","article-title":"Rise of antibody-drug conjugates: the present and future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"B10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013Negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B12","volume-title":"Breast cancer among women younger than 45","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"108296","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B14","unstructured":"TACSTD2 RNA expression summary - the human protein atlas\n          \n          \n          2025"},{"key":"B15","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S585","DOI":"10.1016\/j.annonc.2021.08.1036","article-title":"514O an open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors","volume":"32","author":"Rodon","year":"2021","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.557","article-title":"380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer (mBC): results from a phase I\/II, single-arm, basket trial","volume":"34","author":"Ouyang","year":"2023","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","article-title":"Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","volume":"18","author":"Ouyang","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/jco.2025.43.16_suppl.1019","article-title":"Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from the phase II OptiTROP-Breast05 study","volume":"43","author":"Yin","year":"2025","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.annonc.2022.03.049","article-title":"34P Quadruple-negative breast cancer (PD-L1-negative triple-negative breast cancer, TNBC): poorer response to chemotherapy and poorer survival compared to other TNBCs: a systematic review and meta-analysis","volume":"33","author":"Kassem","year":"2022","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/jco.2024.42.16_suppl.104","article-title":"Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41571-025-01022-0","article-title":"Sacituzumab tirumotecan improves OS in mTNBC","volume":"22","author":"Killock","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.rsurfi.2025.100529","article-title":"Advances in nanoparticles in targeted drug delivery\u2013A review","volume":"19","author":"Islam","year":"2025","journal-title":"Results Surf Inter"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.17_suppl.lba109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"B26","volume-title":"First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: primary results from the randomised, phase 3 TROPION-Breast02 trial","author":"Dent","year":"2025"},{"key":"B27","volume-title":"Primary results from ASCENT-03: a randomized phase 3 study of sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer who are unable to receive PD-(L)1 inhibitors","author":"Cort\u00e9s","year":"2025"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e28385","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.25251\/12yhc207","article-title":"Antibody-drug conjugate induced hair loss responds to minoxidil: a case report","volume":"9","author":"Kaufman","year":"2025","journal-title":"SKIN J Cutan Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"oyaf031","DOI":"10.1093\/oncolo\/oyaf031","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Meric-Bernstam","year":"2025","journal-title":"The Oncologist"},{"key":"B32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/pharmaceutics17020258","article-title":"Understanding the toxicity profile of approved ADCs","volume":"17","author":"Ballest\u00edn","year":"2025","journal-title":"Pharmaceutics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/JTO.0b013e31824b23cb","article-title":"Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients","volume":"7","author":"Kim","year":"2012","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1200\/jco.2025.43.16_suppl.8507","article-title":"Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): results from the randomized OptiTROP-Lung03 study","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"GS1","DOI":"10.1158\/1538-7445.SABCS22-GS1-11","article-title":"Abstract GS1-11: Sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+\/HER2\u2013 metastatic breast cancer (mBC)","volume":"83","author":"Rugo","year":"2023","journal-title":"Cancer Res"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1781533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:46:07Z","timestamp":1770273967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1781533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":35,"alternative-id":["10.3389\/or.2026.1781533"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1781533","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1781533"}}